Although smoking is the main risk factor, adenocarcinoma is also the most common
type of lung cancer among lifelong non-smokers, and the risk of lung cancer is increased by 20 to 30 percent by exposure to secondhand smoke.
An anti-PD-1 antibody developed by Bristol - Myers Squibb generates excitement with results from a phase I trial showing that,
among 236 patients with various
types of cancer, the treatment shrank tumors in 28 percent
of melanoma patients, 30 percent
of patients with kidney
cancer, and 18 percent
of patients with advanced non-small cell
lung cancer.
$ 1.8 M Supports
Cancer Drug Discovery on Commonly Mutated Gene New Brunswick Patch — April 5, 2016 Behavioral Scientist Shares Insights about FDA's Proposed Rule on Banning Tanning Bed Use
among Minors News-Medical.net - March 19, 2016 Intervention Program Reduces Caregiver Distress during Hospitalization
of Pediatric Stem Cell Transplant Patients News-Medical.net - March 9, 2016 Exploring Genomic Pathways in the Development
of Ovarian
Cancer GMNews.com - March 2, 2016 Differences in
Type of Small Protein may further Elucidate
Lung Cancer Risk in African Americans ScienceDaily.com - March 2, 2016 Study Looks at Post-Treatment Resources for Prostate
Cancer Patients Transitioning to Survivorship News-Medical.net - February 11, 2016 Drawing the Line on Tanning Bed Use by Teens ScienceDaily.com - December 21, 2015 What Rutgers Study Uncovered about E-Cigarette Use NJBiz.com - December 9, 2015 Identification
of Barrier that Prevents Progression
of Benign Kidney Tumors to Malignant Disease MedicalNewsToday.com - November, 24, 2015 What is the Color
of the
Lung Cancer Ribbon?
Pharmaceutical giant Merck's flagship immunotherapy drug that was just approved by the United States Food and Drug Administration (FDA) shows promise in the overall survival rate
among patients suffering from one
of the deadliest
type of cancer that affects the
lungs.